Figure 5. miR-155 activates the PI3K/Akt signaling pathway by targeting SHIP1.A and B show a schematic layout and the western blot results for the expression of p-Akt (Panel A) and SHIP1 (Panel B) in response to VEGF treatment with or without incubation with anti-miR-155. C and D show a schematic layout and western blot images of the expression of p-Akt (Ser473; Panel C) and SHIP1 (Panel D) after anti-miR-155 treatment in the OIR and CNV mouse models. Western blot results demonstrated that anti-miR-155 attenuated
the expression of p-Akt (Ser473) and upregulated SHIP1 compared with the control group. All experiments were repeated at least
three times. The data are presented as mean ± SEM. *p<0.05.